Terms: = Breast cancer AND ATRX, P46100, ZNF-HX, XNP, XH2, SHS, SFM1, RAD54, MRXHF1, MGC2094, ATR2, 546 AND Prognosis
26 results:
1. Expression of neuroendocrine markers predicts increased survival in triple-negative breast cancer patients.
Xia C; Shen S; Pang J; Chen L; Yan J; Liang Z; Ren X
Front Endocrinol (Lausanne); 2023; 14():1205631. PubMed ID: 38125789
[TBL] [Abstract] [Full Text] [Related]
2. Analysis of factors influencing the pathological complete remission (ipCR) in patients with internal mammary lymph node metastasis after neoadjuvant chemotherapy.
Li Y; Fei Y
PeerJ; 2023; 11():e16141. PubMed ID: 37818328
[TBL] [Abstract] [Full Text] [Related]
3. Genetic Aspects of Conjunctival Melanoma: A Review.
Chang E; Demirci H; Demirci FY
Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761808
[TBL] [Abstract] [Full Text] [Related]
4. cancer profiles in China and comparisons with the USA: a comprehensive analysis in the incidence, mortality, survival, staging, and attribution to risk factors.
He S; Xia C; Li H; Cao M; Yang F; Yan X; Zhang S; Teng Y; Li Q; Chen W
Sci China Life Sci; 2024 Jan; 67(1):122-131. PubMed ID: 37755589
[TBL] [Abstract] [Full Text] [Related]
5. Serotonin 5-HT7 receptor is a biomarker poor prognostic factor and induces proliferation of triple-negative breast cancer cells through FOXM1.
Cınar V; Hamurcu Z; Guler A; Nurdinov N; Ozpolat B
Breast Cancer; 2022 Nov; 29(6):1106-1120. PubMed ID: 36006564
[TBL] [Abstract] [Full Text] [Related]
6. Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer.
Almstedt K; Heimes AS; Kappenberg F; Battista MJ; Lehr HA; Krajnak S; Lebrecht A; Gehrmann M; Stewen K; Brenner W; Weikel W; Rahnenführer J; Hengstler JG; Hasenburg A; Schmidt M
Eur J Cancer; 2022 Sep; 173():10-19. PubMed ID: 35839597
[TBL] [Abstract] [Full Text] [Related]
7. Development and validation of a computed tomography-based immune ecosystem diversity index as an imaging biomarker in non-small cell lung cancer.
He L; Li ZH; Yan LX; Chen X; Sanduleanu S; Zhong WZ; Lambin P; Ye ZX; Sun YS; Liu YL; Qu JR; Wu L; Tu CL; Scrivener M; Pieters T; Coche E; Yang Q; Yang M; Liang CH; Huang YQ; Liu ZY
Eur Radiol; 2022 Dec; 32(12):8726-8736. PubMed ID: 35639145
[TBL] [Abstract] [Full Text] [Related]
8. Association between contralateral background parenchymal enhancement on MRI and outcome in patients with unilateral invasive breast cancer receiving neoadjuvant chemotherapy.
Rella R; Bufi E; Belli P; Scrofani AR; Petta F; Borghetti A; Marazzi F; Valentini V; Manfredi R
Diagn Interv Imaging; 2022 Oct; 103(10):486-494. PubMed ID: 35585020
[TBL] [Abstract] [Full Text] [Related]
9. EZH2 Protein Expression in Triple-negative breast cancer Treated With Neoadjuvant Chemotherapy: An Exploratory Study of Association With Tumor Response and prognosis.
Fineberg S; Tian X; Makower D; Harigopal M; Lo Y
Appl Immunohistochem Mol Morphol; 2022 Mar; 30(3):157-164. PubMed ID: 35262520
[TBL] [Abstract] [Full Text] [Related]
10. Impact of DAXX and atrx expression on telomere length and prognosis of breast cancer patients.
Hussien MT; Shaban S; Temerik DF; Helal SR; Mosad E; Elgammal S; Mostafa A; Hassan E; Ibrahim A
J Egypt Natl Canc Inst; 2020 Aug; 32(1):34. PubMed ID: 32856116
[TBL] [Abstract] [Full Text] [Related]
11. A methylomics-associated nomogram predicts recurrence-free survival of thyroid papillary carcinoma.
Chen H; Ma X; Yang M; Wang M; Li L; Huang T
Cancer Med; 2020 Oct; 9(19):7183-7193. PubMed ID: 32783399
[TBL] [Abstract] [Full Text] [Related]
12. rad54B potentiates tumor growth and predicts poor prognosis of patients with luminal A breast cancer.
Zhang Z; Li X; Han Y; Ji T; Huang X; Gao Q; Ma D
Biomed Pharmacother; 2019 Oct; 118():109341. PubMed ID: 31545289
[TBL] [Abstract] [Full Text] [Related]
13. Relationship between Clinicopathologic Variables in breast cancer Overall Survival Using Biogeography-Based Optimization Algorithm.
Chuang LY; Chen GY; Moi SH; Ou-Yang F; Hou MF; Yang CH
Biomed Res Int; 2019; 2019():2304128. PubMed ID: 31058185
[TBL] [Abstract] [Full Text] [Related]
14. Diagnostic pathways and management in women with pregnancy-associated breast cancer (PABC): no evidence of treatment delays following a first healthcare contact.
Johansson ALV; Weibull CE; Fredriksson I; Lambe M
Breast Cancer Res Treat; 2019 Apr; 174(2):489-503. PubMed ID: 30552644
[TBL] [Abstract] [Full Text] [Related]
15. SYCP2 expression is a novel prognostic biomarker in luminal A/B breast cancer.
Wu C; Tuo Y
Future Oncol; 2019 Mar; 15(8):817-826. PubMed ID: 30511892
[TBL] [Abstract] [Full Text] [Related]
16. Long-term prognostic implications of risk factors associated with tumor size: a case study of women regularly attending screening.
Strand F; Humphreys K; Holm J; Eriksson M; Törnberg S; Hall P; Azavedo E; Czene K
Breast Cancer Res; 2018 Apr; 20(1):31. PubMed ID: 29669579
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic and functional role of subtype-specific tumor-stroma interaction in breast cancer.
Merlino G; Miodini P; Callari M; D'Aiuto F; Cappelletti V; Daidone MG
Mol Oncol; 2017 Oct; 11(10):1399-1412. PubMed ID: 28672102
[TBL] [Abstract] [Full Text] [Related]
18. Expression of PD-L1 and prognosis in breast cancer: a meta-analysis.
Zhang M; Sun H; Zhao S; Wang Y; Pu H; Wang Y; Zhang Q
Oncotarget; 2017 May; 8(19):31347-31354. PubMed ID: 28430626
[TBL] [Abstract] [Full Text] [Related]
19. Correlation between serum level of chemokine (C-C motif) ligand 18 and poor prognosis in breast cancer.
Sun JH; Fan N; Zhang Y
Genet Mol Res; 2016 Sep; 15(3):. PubMed ID: 27706714
[TBL] [Abstract] [Full Text] [Related]
20. Trends in Obesity Prevalence in Adults With a History of cancer: Results From the US National Health Interview Survey, 1997 to 2014.
Greenlee H; Shi Z; Sardo Molmenti CL; Rundle A; Tsai WY
J Clin Oncol; 2016 Sep; 34(26):3133-40. PubMed ID: 27458295
[TBL] [Abstract] [Full Text] [Related]
[Next]
